Printer Friendly

BLOCK DRUG CORPORATION ANNOUNCES PROMOTION OF HABITROL (NICOTINE TRANSDERMAL SYSTEM) TO DENTAL PROFESSIONALS

BLOCK   DRUG   CORPORATION   ANNOUNCES   PROMOTION  OF  HABITROL  (NICOTINE
    TRANSDERMAL SYSTEM) TO DENTAL PROFESSIONALS
    JERSEY CITY, N.J., Sept. 30 /PRNewswire/ -- Block Drug Corporation (NASDAQ-NMS: BLOCA) today announced an agreement for the promotion of Habitrol(TM) (nicotine transdermal system), a product of the Pharmaceuticals Division of Ciba-Geigy Corporation.  Habitrol is indicated as an aid to smoking cessation for the relief of nicotine withdrawal symptoms and should be used as part of a comprehensive behavioral smoking cessation program.  The product was cleared for marketing by the U.S. Food and Drug Administration in November 1991.  It is available only with a prescription.
    Under the terms of the agreement, Block Drug Corporation has exclusive rights to market and promote the Habitrol patch to dental professionals in the continental United States and Hawaii through its national network of Dental Sales Consultants.  Block will encourage the dentist to prescribe the product as part of a comprehensive behavioral smoking cessation program.  Habitrol is the No. 1 prescribed nicotine patch(A).
    Block Drug Corporation will begin marketing the Habitrol brand to the dental professional on or about Oct. 1, 1992.  Financial terms of the agreement have not been disclosed.
    "This agreement for the co-promotion of Habitrol(TM) (nicotine transdermal system) underscores the key role dental intervention should play in helping motivated smokers to understand how quitting can improve oral and overall health," said Michael C. Alfano, D.M.D., Ph.D., senior vice president, director, r{esearch and technology for Block Drug Company, Inc.
    Block markets professional and consumer dental products nationally and internationally.  Among the branded dental products it markets are the Sensodyne(R) line of desensitizing dentifrices, the Vital Defense(TM) line of dental office infection control products, the Mynol(R) line of endodontic products, and the Py-Co-Pay(R) Softex and Sensodyne Search(R) lines of toothbrushes.  Block Drug Corporation is a subsidiary of Block Drug Company, Inc., a "Fortune 500" company.
    Ciba-Geigy is a leading developer, manufacturer and marketer of pharmaceuticals, with U.S. pharmaceutical headquarters in Summit, N.J.
    NOTE:  Advise patients not to smoke or use other nicotine-containing products while receiving Habitrol Treatment.
    Habitrol should not be used for more than three months.  The effects of Habitrol treatment on fetal development are unknown.  Pregnant or nursing smokers should be encouraged to attempt smoking cessation using nonpharmacologic approaches before using Habitrol.  The risks vs. benefit of nicotine replacement should be weighed in patients with certain cardiovascular and peripheral vascular diseases.  Certain concomitant medications may need dosage adjustments (see Drug Interactions section of complete prescribing information).  Used and unused systems should be kept out of the reach of children and pets.
    (A) Based on PDS data from January through August 1992.  Complete information on Habitrol safety and efficacy is in the Prescribing Information which can be obtained from either of contacts listed.
    -0-             09/30/92
    CONTACT:  Dean Siegal of Block Drug Company, Inc., 201-434-3000, ext. 1514, or Doug Arbesfeld of Ciba-Geigy Corporation, 908-277-5758, for Block Drug Company, Inc.
    (BLOCA) CO:  BLOCK DRUG CORPORATION IN:  MTC ST:  NJ -- NY051 -- X564  09/30/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1992
Words:509
Previous Article:ATLANTECH TECHNOLOGIES TO INCORPORATE AT&T PARADYNE TRANSMISSION TECHNOLOGIES IN PRODUCT LINE
Next Article:ONONDAGA CO. (N.Y.) GENERAL OBLIGATION BONDS RATED 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
CYGNUS: LEADING RUSSIAN SCIENTISTS JOIN CYGNUS ELECTROPORATION TEAM
SIX STEPS HELP SMOKERS QUIT AND STAY SMOKE-FREE
SANDOZ AND MARION MERRELL DOW ANNOUNCE CO-PROMOTION ARRANGEMENT
BLOCK DRUG CORPORATION AND WYETH-AYERST LABORATORIES TO CO-PROMOTE LODINE (ETODOLAC) TO DENTISTS
CIBA TO TRANSFER MARKETING OF NICOTINE PATCH TO CONSUMER UNIT
PHARMA PATCH PLC COMPLETES AGREEMENTS WITH PHARMACIA AB
BLOCK DRUG COMPANY AND U.S. BIOMATERIALS CORPORATION ENTER INTO AN AGREEMENT
HOECHST MARION ROUSSEL, ALZA CORPORATION AND CIBA-GEIGY SETTLE NICOTINE PATCH PATENT LITIGATION
Nastech Signs Drug Development Agreement With Ciba Self-Medication, Inc.
Sano Corporation Amends Generic Product Distribution Agreement

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters